Literature DB >> 28208059

Designer protein disaggregases to counter neurodegenerative disease.

James Shorter1.   

Abstract

Protein misfolding and aggregation unify several devastating neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. There are no effective therapeutics for these disorders and none that target the reversal of the aberrant protein misfolding and aggregation that cause disease. Here, I showcase important advances to define, engineer, and apply protein disaggregases to mitigate deleterious protein misfolding and counter neurodegeneration. I focus on two exogenous protein disaggregases, Hsp104 from yeast and gene 3 protein from bacteriophages, as well as endogenous human protein disaggregases, including: (a) Hsp110, Hsp70, Hsp40, and small heat-shock proteins; (b) HtrA1; and (c) NMNAT2 and Hsp90. I suggest that protein-disaggregase modalities can be channeled to treat numerous fatal and presently incurable neurodegenerative diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28208059      PMCID: PMC5447488          DOI: 10.1016/j.gde.2017.01.008

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  110 in total

1.  Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates.

Authors:  Annette Tennstaedt; Simon Pöpsel; Linda Truebestein; Patrick Hauske; Anke Brockmann; Nina Schmidt; Inga Irle; Barbara Sacca; Christof M Niemeyer; Roland Brandt; Hanna Ksiezak-Reding; Anca Laura Tirniceriu; Rupert Egensperger; Alfonso Baldi; Leif Dehmelt; Markus Kaiser; Robert Huber; Tim Clausen; Michael Ehrmann
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

2.  Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions.

Authors:  James Shorter; Susan Lindquist
Journal:  EMBO J       Date:  2008-10-02       Impact factor: 11.598

3.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

4.  Metazoan Hsp70 machines use Hsp110 to power protein disaggregation.

Authors:  Heike Rampelt; Janine Kirstein-Miles; Nadinath B Nillegoda; Kang Chi; Sebastian R Scholz; Richard I Morimoto; Bernd Bukau
Journal:  EMBO J       Date:  2012-09-18       Impact factor: 11.598

5.  Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death.

Authors:  A-L Mahul-Mellier; F Vercruysse; B Maco; N Ait-Bouziad; M De Roo; D Muller; H A Lashuel
Journal:  Cell Death Differ       Date:  2015-07-03       Impact factor: 15.828

6.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

Review 8.  Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.

Authors:  Toshiki Uchihara; Benoit I Giasson
Journal:  Acta Neuropathol       Date:  2015-10-07       Impact factor: 17.088

9.  Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein.

Authors:  Marcus D Tuttle; Gemma Comellas; Andrew J Nieuwkoop; Dustin J Covell; Deborah A Berthold; Kathryn D Kloepper; Joseph M Courtney; Jae K Kim; Alexander M Barclay; Amy Kendall; William Wan; Gerald Stubbs; Charles D Schwieters; Virginia M Y Lee; Julia M George; Chad M Rienstra
Journal:  Nat Struct Mol Biol       Date:  2016-03-28       Impact factor: 15.369

10.  Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation.

Authors:  Alexander K Buell; Céline Galvagnion; Ricardo Gaspar; Emma Sparr; Michele Vendruscolo; Tuomas P J Knowles; Sara Linse; Christopher M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

View more
  34 in total

1.  Repeat-associated non-ATG (RAN) translation.

Authors:  John Douglas Cleary; Amrutha Pattamatta; Laura P W Ranum
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

Review 2.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 3.  Molecular chaperones in the brain endothelial barrier: neurotoxicity or neuroprotection?

Authors:  Dominique Thuringer; Carmen Garrido
Journal:  FASEB J       Date:  2019-07-26       Impact factor: 5.191

Review 4.  Spiraling in Control: Structures and Mechanisms of the Hsp104 Disaggregase.

Authors:  James Shorter; Daniel R Southworth
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-08-01       Impact factor: 10.005

5.  Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain.

Authors:  Amber Tariq; JiaBei Lin; Megan M Noll; Mariana P Torrente; Korrie L Mack; Oscar Hernandez Murillo; Meredith E Jackrel; James Shorter
Journal:  FEMS Yeast Res       Date:  2018-08-01       Impact factor: 2.796

Review 6.  The molecular language of membraneless organelles.

Authors:  Edward Gomes; James Shorter
Journal:  J Biol Chem       Date:  2018-07-25       Impact factor: 5.157

7.  Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD.

Authors:  Hana M Odeh; James Shorter
Journal:  Emerg Top Life Sci       Date:  2020-12-11

Review 8.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

9.  Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy.

Authors:  Emily E Blythe; Kristine C Olson; Vincent Chau; Raymond J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-16       Impact factor: 11.205

10.  Ubiquilin 2: Shuttling Clients Out of Phase?

Authors:  Ipsita Subudhi; James Shorter
Journal:  Mol Cell       Date:  2018-03-15       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.